What the PCOS-PMOS Rebrand Tells Us About the State of Women’s Health Research

The announcement in May of 2026 that polycystic ovarian syndrome (PCOS) will be renamed polyendocrine metabolic ovarian syndrome (PMOS) was a genuine milestone. After 14 years of global collaboration, 22,000 survey responses and workshops spanning every inhabited continent, researchers and patients finally agreed on a name that reflects what the condition actually is: not a quirk of the ovaries, but a complex, multi-system disorder of hormones, metabolism, and endocrine function affecting one in eight women worldwide.

For decades, the term polycystic had patients and clinicians alike focusing on ovarian cysts, while metabolic dysfunction and insulin resistance went underappreciated and undertreated. Patients report feeling dismissed, confused, and dissatisfied with their care. The very name, researchers concluded, contributed to stigma, delayed diagnosis and fragmented policy.

But renaming a disease is not the same as researching it. And for women’s health, the research has been underfunded and undervalued for so long that a vocabulary fix (however warranted) cannot close the gap on its own.

The post What the PCOS-PMOS Rebrand Tells Us About the State of Women’s Health Research appeared first on Ms. Magazine.